<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth Henske, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tuberous sclerosis complex (TSC) is a disorder characterized by multiple benign tumors, and rarely malignant neoplasms of the skin, brain, eyes, heart, lung, liver, and kidney [<a href="#rid1">1,2</a>]. TSC is caused by mutations in the TSC1 or TSC2 gene and is transmitted as an autosomal dominant trait in one-third of cases while nonfamilial cases represent either spontaneous mutations or mosaicism. (See  <a class="medical medical_review" href="/d/html/142618.html" rel="external">"Tuberous sclerosis complex: Genetics and pathogenesis", section on 'Genetics'</a>.)</p><p>Lymphangioleiomyomatosis (LAM) is a multisystem disorder that primarily affects the lung. It can occur sporadically (sporadic-LAM) or in association with TSC (TSC-LAM). Many clinical, radiologic, and pathologic features are shared between TSC and sporadic variants. This review will focus on the elements of LAM that are specific to TSC. The epidemiology, diagnosis, and management of sporadic-LAM and TSC are discussed separately. (See  <a class="medical medical_review" href="/d/html/4335.html" rel="external">"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation"</a> and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p class="headingAnchor" id="H88312680"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Sporadic lymphangioleiomyomatosis (sporadic-LAM) is rare and almost exclusively affects females, with estimates of up to 8 cases per million females (see  <a class="medical medical_review" href="/d/html/4335.html" rel="external">"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis", section on 'Epidemiology'</a>). In contrast, TSC, an autosomal dominant genetic disorder, has an incidence of approximately 1 in 5000 to 10,000 live births with a high prevalence of LAM among adults [<a href="#rid3">3</a>]. Obtaining exact prevalence rates of TSC-LAM is challenging since data are derived from small retrospective observational studies that mostly utilize computed tomographic (CT) evidence of cystic lung disease for diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Several studies report prevalence rates in females with TSC (mostly TSC2 mutations) that range from 26 to 50 percent [<a href="#rid4">4-9</a>]. Rates increase with age after 15 years with the highest rates (up to 80 percent) reported in females over the age of 40 years and lowest rates (27 percent) in those &lt;21 years [<a href="#rid8">8,10</a>]. Based upon the worldwide prevalence of over one million people and a conservative projection that 30 percent of females with TSC develop cystic changes consistent with LAM, it is estimated that the number of females with TSC-LAM and/or cystic changes consistent with LAM is over 100,000. However, the majority of females with TSC-LAM have normal lung function.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unlike sporadic-LAM, which is extremely rare in males, LAM can occur in males with TSC. The rates of cystic lung disease in males with TSC range from 10 to 38 percent, although the development of symptomatic disease or a decline in lung function is exceptionally rare in males [<a href="#rid9">9,11,12</a>]. </p><p></p><p>Epidemiologic features of sporadic-LAM are discussed separately. (See  <a class="medical medical_review" href="/d/html/4335.html" rel="external">"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H1325629283"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The sporadic and tuberous sclerosis complex (TSC)-associated forms of lymphangioleiomyomatosis (LAM) are identical pathologically [<a href="#rid4">4</a>]. The high prevalence of LAM in TSC has led to the identification of a critical role for mutations in the TSC genes, particularly TSC2, in the smooth muscle cell proliferation which is characteristic of LAM lesions. In support of this hypothesis, LAM mostly occurs among patients with TSC2 mutations and is rare in patients with TSC1 mutations [<a href="#rid7">7</a>]. As an example, in a cohort study of 55 females with TSC, among the 23 females with cysts characteristic of LAM, 16 had TSC2 mutations while the remaining seven had no mutation identified [<a href="#rid13">13</a>]. In addition, the prevalence of LAM was higher in females with <em>TSC2</em> mutations compared with females with <em>TSC1</em> mutations (55 percent versus 0 percent). The pathogenesis of LAM discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4335.html" rel="external">"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H641776278"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In most patients, the diagnosis of TSC is known. Data derived from small observational studies of TSC patients [<a href="#rid4">4-12,14</a>] and larger studies that included TSC-LAM and sporadic-LAM suggest that the respiratory manifestations of TSC-LAM and sporadic-LAM are similar. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H626135459"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Features of LAM specific to TSC include the following [<a href="#rid10">10,14-16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The classic TSC features including cognitive disability and seizures can be absent in TSC-LAM (ie, "milder" version of TSC) [<a href="#rid15">15</a>], although this is not always the case [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TSC-LAM is more commonly encountered in those with TSC2 rather than TSC1 mutations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relative to other complications of TSC, such as seizures that are often diagnosed in early childhood, LAM is a later manifestation during the course of TSC, typically from late adolescence through adulthood. Symptoms generally develop in the third decade of life and are uncommon before age 20.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal angiomyolipomas (AMLs) are more frequent in TSC-LAM (&gt;80 percent) and are often bilateral, when compared with sporadic-LAM (30 percent incidence of angiomyolipomas).  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphatic complications such as chylothorax, chylous ascites, and lymphangioleiomyomas may be less common in patients with TSC-LAM than sporadic-LAM [<a href="#rid17">17-19</a>], although results vary [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with TSC-LAM may also have polycystic kidney disease since the PKD1 (polycystic kidney disease 1) and TSC2 genes are adjacent on chromosome 16p13, and a contiguous gene syndrome involving partial or complete deletion of both genes can occur.   </p><p></p><p class="headingAnchor" id="H2537220776"><span class="h2">Imaging characteristics</span><span class="headingEndMark"> — </span>Several studies have reported pulmonary cysts in TSC-LAM identical to those seen in sporadic-LAM [<a href="#rid5">5,6,9,17,20,21</a>]. Cysts are thin-walled, multiple (≥10), diffuse, round, well-defined, and bilateral. They vary in size and are devoid of internal structures. Further details are provided separately. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Imaging'</a>.)</p><p>Specific to TSC:</p><p class="bulletIndent1"><span class="glyph">●</span>Cysts may be larger and more numerous in females than males with TSC [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fewer cysts may occur in TSC-LAM (ie, milder disease) than the sporadic variant, although this may represent ascertainment bias [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal AMLs, visualized on abdominal cuts of high resolution computed tomography (HRCT) chest or a dedicated abdominal CT scan, are more frequent in patients with TSC-LAM (often &gt;80 percent) compared with sporadic-LAM (30 percent)  (<a class="graphic graphic_diagnosticimage graphicRef50146" href="/d/graphic/50146.html" rel="external">image 1</a>) [<a href="#rid5">5,11,14</a>]. In addition, they are often large, multiple, and bilateral. In a series of males with TSC, renal AMLs were present in 14 of 25 patients with available imaging [<a href="#rid11">11</a>]. In a separate series among females with TSC-LAM, all had AMLS that were larger and required more interventions, when compared with females with TSC who did not have LAM [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Renal angiomyolipomas'</a> and  <a class="medical medical_review" href="/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HRCT chest in patients with TSC-LAM may also identify multifocal micronodular pneumocyte hyperplasia (MMPH), a feature rarely seen with sporadic LAM. (See <a class="local">'Multifocal micronodular pneumocyte hyperplasia'</a> below.)</p><p></p><p class="headingAnchor" id="H448671404"><span class="h1">SCREENING FOR TSC-LAM</span><span class="headingEndMark"> — </span>Although not definitively proven, based upon the reported high prevalence of LAM in this population, International Tuberous Sclerosis Complex Consensus Group recommendations suggest that screening of asymptomatic females 18 years and older should be with chest computed tomography (CT) using a low-dose noncontrast protocol [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One single-center retrospective review of initial chest CT scans performed in 133 female patients with TSC aged ≥15 years over a 12-year period, reported that 50 percent of patients had cysts consistent with LAM [<a href="#rid8">8</a>]. The risk of LAM was age dependent, rising by about 8 percent per year. Among asymptomatic patients, 84 had cysts identified on a single slice at the level of the carina. Most patients (two-thirds) with cysts eventually developed pulmonary symptoms and a smaller proportion (13 percent) died from LAM. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study prospectively screened 23 asymptomatic females with TSC high-resolution computed tomography (HRCT) [<a href="#rid5">5</a>] and found cystic pulmonary parenchymal changes consistent with LAM in 39 percent. These patients were older than cyst-negative patients (32 versus 25 years). All cyst-positive patients had angiomyolipomas (AML), which were larger than those in cyst-negative patients.</p><p></p><p>If the CT chest reveals no cysts, we typically repeat a chest CT every 5 to 10 years or if symptoms emerge. If cystic lung disease consistent with LAM is identified, we proceed with baseline pulmonary function tests (PFTs; pre- and post-bronchodilator spirometry, lung volumes, and diffusing capacity for carbon monoxide) and a six-minute walk test to evaluate the degree of respiratory impairment.</p><p>Longitudinal serial measurement of serum vascular endothelial growth factor-D (VEGF-D) may be useful to detect the development of LAM in women with TSC [<a href="#rid13">13</a>]. However, VEGF-D has not been tested prospectively as a screening tool for TSC-LAM.</p><p class="headingAnchor" id="H864031253"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>LAM should be suspected in any TSC patient (males and females) with symptoms and signs consistent with LAM (eg, progressive dyspnea, cough, pneumothorax, chylothorax). The diagnostic evaluation of TSC-LAM should be done in conjunction with an expert in TSC and LAM.</p><p>Our approach to the diagnosis of TSC-LAM is described in the algorithm  (<a class="graphic graphic_algorithm graphicRef111073" href="/d/graphic/111073.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1007490661"><span class="h2">High resolution computed tomography</span><span class="headingEndMark"> — </span>In males and females of any age with a <strong>known</strong> diagnosis of TSC and respiratory symptoms, we suggest noncontrast high resolution computed tomography (HRCT) of the chest  (<a class="graphic graphic_algorithm graphicRef111073" href="/d/graphic/111073.html" rel="external">algorithm 1</a>) [<a href="#rid12">12</a>]. The rationale for performing noncontrast HRCT is based upon the principle that typical cysts, the hallmark lesion in LAM, are seen in almost every patient with LAM and that cysts are often undetectable on routine chest radiography. Upper abdominal images obtained at the same time may detect coexistent angiomyolipomas. (See <a class="local">'Imaging characteristics'</a> above.)</p><p>Depending on the HRCT chest findings, we next perform the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung cysts consistent with LAM</strong> – The identification of multiple cysts consistent with LAM on HRCT in a patient with TSC provides a clinical diagnosis of LAM and, in most patients, avoids the need for definitive biopsy (see <a class="local">'Imaging characteristics'</a> above). Once cysts are identified, we typically obtain a vascular endothelial growth factor-D (VEGF-D level), which, if elevated (≥800 pg/mL), provides further support for the diagnosis. Imaging characteristics of sporadic-LAM on HRCT chest and details regarding the diagnostic value of VEGF-D are provided separately. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Tuberous sclerosis complex'</a> and <a class="local">'Vascular endothelial growth factor-D'</a> below and <a class="local">'Imaging characteristics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No lung cysts</strong> – If the HRCT chest reveals no cysts, we evaluate for other potential causes of respiratory symptoms. Pulmonary function tests provide a starting point for this evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical cysts</strong> – If the HRCT reveals atypical cysts, a low number of cysts (eg, &lt;10), or is suspicious for an alternate diagnosis, the approach should be individualized. Options include obtaining a VEGF-D level, investigating for an alternate diagnosis, follow up HRCT, and (rarely) lung biopsy. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Other presentations'</a>.)</p><p></p><p>Occasionally, the diagnosis of TSC is <strong>not known,</strong> but is discovered during the evaluation of cystic lung disease because of a family history or characteristic cutaneous manifestations of TSC. In such cases, obtaining a definitive diagnosis of TSC (ie, clinical criteria and/or genetic testing) under the guidance of a TSC expert  (<a class="graphic graphic_table graphicRef66759" href="/d/graphic/66759.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef111073" href="/d/graphic/111073.html" rel="external">algorithm 1</a>) is appropriate since a diagnosis of TSC will eliminate the need for tissue biopsy (see  <a class="medical medical_review" href="/d/html/143210.html" rel="external">"Tuberous sclerosis complex: Evaluation and diagnosis"</a>). The rationale for performing noncontrast HRCT of the chest is to identify typical cysts, the hallmark lesion in LAM. (See <a class="local">'Imaging characteristics'</a> above.)</p><p class="headingAnchor" id="H2332478120"><span class="h2">Pulmonary function testing</span><span class="headingEndMark"> — </span>While pulmonary function abnormalities can be nonspecific, patients with suspected TSC-LAM who are able should undergo pulmonary function tests (PFTs), including spirometry (pre- and post-bronchodilator), lung volumes, diffusing capacity for carbon monoxide (DLCO), and a six-minute walk test to evaluate the degree of respiratory impairment [<a href="#rid3">3</a>].</p><p>Although some experts use PFTs to screen asymptomatic females with TSC aged 18 years or older for development of LAM, it is often done in conjunction with HRCT. There is no validity to using PFTS alone as a screening tool since they are nonspecific, and a normal study does not preclude the diagnosis of LAM; HRCT is a more sensitive tool. Obtaining a baseline set of PFTs in females with TSC and cystic lung disease can be an important metric for future follow up evaluation.</p><p>PFT abnormalities, when present, are similar to those in patients with sporadic-LAM (eg, airflow limitation, restriction or mixed deficit, reduction in DLCO), the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Pulmonary function tests'</a>.)</p><p>Although observational studies in females with TSC-LAM suggest milder impairment in lung function, when compared with females with sporadic-LAM, this may relate to ascertainment bias [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Pulmonary function tests'</a>.)</p><p class="headingAnchor" id="H1957222"><span class="h2">Vascular endothelial growth factor-D</span><span class="headingEndMark"> — </span>Serum VEGF-D, a lymphangiogenic growth factor, can be elevated in TSC-LAM [<a href="#rid23">23,24</a>]. A VEGF-D level of ≥800 pg/mL is typically used as the diagnostic cut-off and may distinguish LAM (TSC or sporadic) from other causes of cystic lung disease but may not distinguish TSC-LAM from sporadic-LAM [<a href="#rid24">24</a>] and can be elevated in TSC patients who not have LAM Testing for serum VEGF-D is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.testmenu.com%2Fcincinnatichildrens%2FTests%2F665748&amp;token=9WvejqvB%2BuxLfR5G5o7V61e9JCpbrDZ48uajNJGqhHHk4HwgPVREJ2i8%2BnXt0IKOzcAlwubixrDRqc6w6MnStg%3D%3D&amp;TOPIC_ID=4329" target="_blank">Translational Trials Laboratory at Cincinnati Children's</a>.</p><p>Data supporting the role of VEGF-D testing in females with TSC and suspected LAM include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In one prospective study of patients with cystic lung disease, 28 females with TSC-LAM had higher serum VEGF-D levels, when compared with females who had TSC but did not have LAM or females with cysts from other causes (3465 versus 370 versus 281 pg/mL, respectively) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study, higher VEGF-D levels were reported in females with TSC-LAM compared with sporadic-LAM (2682 versus 1281 pg/mL), although it could not distinguish TSC from the sporadic form of LAM [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another cohort study, higher levels of VEGF-D were seen in patients with TSC and LAM compared with patients who had TSC and did not have LAM (725 pg/mL versus 429 pg/mL) [<a href="#rid13">13</a>]; levels in those without LAM were consistently below 800 pg/mL suggesting that it may have diagnostic value similar to that seen in patients with sporadic LAM when discriminating between those that do an do not have LAM. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Vascular endothelial growth factor-D'</a>.)</p><p></p><p>These and other data regarding VEGF-D are discussed separately. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Vascular endothelial growth factor-D'</a> and  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Vascular endothelial growth factor-D positive'</a>.)</p><p class="headingAnchor" id="H1236827413"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>LAM is the most common cause of lung cysts in patients with TSC, although mimics exist. The differential diagnosis of cystic lung disease in patients with TSC is similar to that in sporadic-LAM, the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H1826168343"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A clinical diagnosis of TSC-LAM is typically made by identifying characteristic high resolution computed tomography (HRCT) findings in patients with an established diagnosis of TSC  (<a class="graphic graphic_table graphicRef66759" href="/d/graphic/66759.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef111073" href="/d/graphic/111073.html" rel="external">algorithm 1</a>) [<a href="#rid12">12,24,26</a>]. The presence of an angiomyolipoma (AML) and/or elevated vascular endothelial growth factor-D (VEGF-D; ≥800 pg/mL) and/or other features of LAM such as a chylous effusion or lymphangioleiomyoma confirm the diagnosis of LAM, but their absence does not preclude it.</p><p>An opportunity may arise to make a definitive diagnosis from lung tissue obtained during thorascopic pleurodesis for pneumothorax or from cytological analysis of chylous pleural or ascitic fluid, but definitive histopathologic diagnosis is generally not necessary. The histopathology of TSC-LAM is identical to that described for sporadic-LAM  (<a class="graphic graphic_picture graphicRef64389 graphicRef53690 graphicRef68405" href="/d/graphic/64389.html" rel="external">picture 1A-C</a> and <a class="graphic graphic_picture graphicRef66775 graphicRef77252" href="/d/graphic/66775.html" rel="external">picture 2A-B</a> and <a class="graphic graphic_picture graphicRef79407" href="/d/graphic/79407.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef55243" href="/d/graphic/55243.html" rel="external">picture 4</a>), the details of which are described separately. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Diagnosis'</a>.)</p><p>Once the diagnosis of TSC-LAM is made, the assessment of disease extent is similar to that of sporadic LAM and is based on respiratory symptoms, HRCT findings, pulmonary function test results, and extrapulmonary complications. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Assessment of disease extent'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of TSC-LAM is identical to that of sporadic-LAM. However, the data to support the same approach is based upon studies that include mostly patients with sporadic-LAM with only a minority of patients with TSC-LAM represented. None of the studies had sufficient power to compare the response between TSC and sporadic populations. TSC-LAM should be managed in conjunction with a TSC and LAM expert. Details are provided separately. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H15448872"><span class="h2">General measures and treatment of complications</span><span class="headingEndMark"> — </span>General measures used to treat TSC-LAM (separately from the use of <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, when appropriate) include avoidance of cigarette smoking, supplemental oxygen for hypoxemia, pulmonary rehabilitation, and bronchodilators, when indicated. Estrogen-containing medications and contraceptives should be avoided, and patients should be informed about the increased risks associated with pregnancy including pneumothorax, chylothorax, lung disease progression, and hemorrhage into angiomyolipomas. These measures as well as management recommendations for air travel, birth control, and management of complications (eg, pneumothorax, chylous accumulations) are discussed separately. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'General measures'</a> and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Treatment of complications'</a>.)</p><p class="headingAnchor" id="H1479651260"><span class="h2">Mild lung function impairment</span><span class="headingEndMark"> — </span>Mild lung function impairment in TSC-LAM is a forced expiratory volume in one second (FEV<sub>1</sub>) 70 percent of predicted or greater, but less than 80 percent predicted. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Normal or mildly impaired lung function'</a>.)</p><p class="headingAnchor" id="H1605700300"><span class="h3">Monitored observation</span><span class="headingEndMark"> — </span>Similar to patients with sporadic LAM, most patients with TSC-LAM who have normal or mildly impaired pulmonary function should undergo monitored observation with interval clinical assessment and pulmonary function testing, rather than initiating mechanistic target of rapamycin (mTOR) inhibitor therapy unless other indications for an mTOR inhibitor pertain (eg, refractory epilepsy, symptomatic subependymal giant cell tumors [SGCTs, also known as subependymal giant cell astrocytomas], lymphatic disease). For patients who are unable to perform pulmonary function tests, we use a combination of clinical judgment, serial levels of vascular endothelial growth factor-D (VEGF-D), and sometime repeat chest computed tomography in order to determine disease trajectory. The details of monitored observation are discussed separately. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Treatment of complications'</a> and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Normal or mildly impaired lung function'</a> and  <a class="medical medical_review" href="/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features", section on 'Subependymal giant cell astrocytomas'</a>.)</p><p class="headingAnchor" id="H716625636"><span class="h2">Moderate to severe lung function impairment</span><span class="headingEndMark"> — </span>Moderate to severe lung function impairment in TSC-LAM is a FEV<sub>1</sub> &lt;70 percent predicted. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Moderate to severe lung function impairment'</a>.)</p><p class="headingAnchor" id="H89124401"><span class="h3">mTOR inhibitors</span><span class="headingEndMark"> — </span>The mTOR inhibitor, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, is first-line therapy for patients with moderate-to-severe TSC-LAM [<a href="#rid3">3</a>]. This approach is based upon data from a randomized trial in which sirolimus slowed the decline in lung function (relative to placebo) in patients with LAM, 9 percent of whom had TSC-LAM [<a href="#rid27">27</a>]. Patient selection, dosing, safety, efficacy, and follow up for those on sirolimus are discussed separately. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Sirolimus (first line)'</a>.)</p><p><a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">Everolimus</a>, another mTOR inhibitor, is generally considered a second-line agent for LAM, although it is FDA-approved for other manifestations of TSC. One open-label trial that included five patients with TSC-LAM reported a similar efficacy and safety profile with everolimus compared to <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid28">28</a>]. Everolimus is approved for the treatment of TSC-related angiomyolipomas (AMLs) and central nervous system tumors (eg, SGCTs]) [<a href="#rid29">29,30</a>]. Thus, in some patients with TSC who have a clear indication for everolimus (eg, SGCTs), it would be appropriate to treat coexistent TSC-LAM on a trial basis with everolimus. Sirolimus and everolimus cannot be used simultaneously. More detailed discussion of mTOR inhibitor dosing, target levels and monitoring in TSC are provided separately. (See  <a class="medical medical_review" href="/d/html/90017.html" rel="external">"Renal angiomyolipomas (AMLs): Management"</a> and  <a class="medical medical_review" href="/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Role of mTOR inhibitor therapy'</a>.)</p><p class="headingAnchor" id="H2503381913"><span class="h2">Refractory disease</span></p><p class="headingAnchor" id="H15448860"><span class="h3">Lung transplantation and clinical trials</span><span class="headingEndMark"> — </span>For patients with advanced TSC-LAM or for those refractory to mTOR inhibitors, clinical trials (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=4329" target="_blank">clinicaltrials.gov</a>) or lung transplantation are the main therapeutic options. While patients with TSC-LAM have been successfully transplanted, antirejection medications may lower the seizure threshold and seizure medications may interfere with antirejection medications [<a href="#rid31">31</a>]. Other recommendations for this population are discussed separately. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Refractory disease'</a>.)</p><p class="headingAnchor" id="H2370713900"><span class="h2">Lymphatic disease and angiomyolipomas</span><span class="headingEndMark"> — </span>Certain extrapulmonary manifestations of TSC-LAM may require treatment in concert with or independently from the lung disease:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chylous accumulations and lymphangioleiomyomas</strong> – mTOR inhibition with <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> is generally the treatment of choice for those with symptomatic chylous accumulations or lymphangioleiomyomas, the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Chylothorax and chylous ascites'</a> and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Other lymphatic disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiomyolipomas</strong> – Selected patients with larger or symptomatic AMLs may require treatment with mTOR inhibition or surgical intervention. The management of AMLs is discussed separately. (See  <a class="medical medical_review" href="/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H1886517368"><span class="h1">FOLLOWUP AND PROGNOSIS</span><span class="headingEndMark"> — </span>Similar to sporadic lymphangioleiomyomatosis (sporadic-LAM), TSC-LAM is a progressive disorder with rates of progression that vary among individuals [<a href="#rid32">32</a>]. Patients with TSC-LAM should be monitored for progressive lung function decline with pulmonary function testing and for the development of complications. The optimal frequency of clinical and pulmonary function test (PFT) assessment is not well-defined. We typically schedule follow-up visits with spirometry pre and post bronchodilator at three to four month intervals and obtain additional studies such as a six-minute walk test (with oximetry) or chest imaging depending on the clinical assessment and PFT results. Further details on the follow up of LAM patients are provided separately. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Monitored observation'</a> and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Monitoring clinical response'</a> and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Treatment of complications'</a>.)</p><p>In adult TSC patients, LAM is a major cause of death  (<a class="graphic graphic_figure graphicRef77767" href="/d/graphic/77767.html" rel="external">figure 1</a>) together with renal disease and sudden death from epilepsy (SUDEP) [<a href="#rid15">15,33,34</a>]. With the advent of mechanistic target of rapamycin (mTOR) inhibitor therapy and aggressive interventional approaches for renal disease, a single-center retrospective study suggests that fewer patients with TSC are dying from renal complications than in the past and that LAM is now the second most common cause of death after SUDEP [<a href="#rid34">34</a>]. It is widely believed among experts that TSC-associated LAM may have a more indolent course than sporadic LAM, although similar rates of decline in lung function have been reported in severity-matched patients [<a href="#rid22">22,35</a>]. One study reported an average life expectancy of TSC-LAM at 63 years [<a href="#rid34">34,35</a>]. Whether males with TSC-LAM live longer than females with TSC-LAM is unknown. The prognosis of TSC and of LAM are discussed separately. (See  <a class="medical medical_review" href="/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H3860521955"><span class="h1">OTHER TUBEROUS SCLEROSIS COMPLEX-RELATED LUNG DISORDERS</span></p><p class="headingAnchor" id="H134382390"><span class="h2">Multifocal micronodular pneumocyte hyperplasia</span><span class="headingEndMark"> — </span>Unlike sporadic lymphangioleiomyomatosis (sporadic-LAM) where multifocal micronodular pneumocyte hyperplasia (MMPH) is rare, MMPH can occur in up to two-thirds of patients with TSC, with or without LAM [<a href="#rid6">6,20,21,36,37</a>]. The etiology MMPH appears to be due to hyperphosphorylated mechanistic target of rapamycin (mTOR)-related proteins which may cause benign proliferation of type II pneumocytes along alveolar septa [<a href="#rid38">38,39</a>].</p><p>MMPH is generally asymptomatic and found incidentally in the lung on imaging or on pathology. Equal proportions of males and females with TSC are affected. On computed tomography, MMPH appears as multiple, centrilobular solid or ground glass nodular opacities ranging in size from 2 to 10 mm scattered throughout lungs in a random distribution.</p><p>MMPH can occur alone or with the cystic changes of LAM and can occur with either TSC1 or TSC2 mutations. In a retrospective study of 66 females with TSC, 28 percent had MMPH alone and a smaller proportion had MMPH in association with LAM. There were no specific clinical or genetic functional features [<a href="#rid14">14</a>]. Similarly, in a prospective study of 23 asymptomatic females with TSC, 43 percent had pulmonary parenchymal nodules which were more common in females with cysts consistent with LAM (78 percent) [<a href="#rid5">5</a>]. Unlike TSC-LAM, which is associated with TSC2 mutations, TSC-associated MMPH was associated with both TSC1 and TSC2 mutations.</p><p>In general, a biopsy is not required unless symptoms or imaging appearance suggests miliary metastases or progressive granulomatous disease. MMPH is generally indolent and nonprogressive [<a href="#rid40">40</a>], and as such no therapy is typically required (or available).</p><p class="headingAnchor" id="H3655090887"><span class="h2">Clear cell tumor of the lung</span><span class="headingEndMark"> — </span>Clear cell ("sugar") tumor of the lung (CCTL) is a rare, typically benign mesenchymal tumor with histologically and immunohistochemically distinctive perivascular epithelioid cells. Rare cases of CCTL have been reported in TSC-LAM [<a href="#rid41">41</a>]. LAM, angiomyolipoma, and CCTL are the major members of the neoplasms with perivascular epithelioid differentiation (ie, PEComa) family of lung tumors. CCTL affects males and females equally and usually presents as a nodule on chest imaging. Unlike pulmonary LAM, both human melanoma black (HMB)-45 staining and S-100 staining are positive.</p><p class="headingAnchor" id="H3028197202"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120578.html" rel="external">"Society guideline links: Tuberous sclerosis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/118842.html" rel="external">"Society guideline links: Lymphangioleiomyomatosis"</a>.)</p><p class="headingAnchor" id="H2990887662"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/117229.html" rel="external">"Patient education: Lymphangioleiomyomatosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3880871734"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/d/html/131727.html" rel="external">"Patient perspective: Lymphangioleiomyomatosis (LAM)"</a>.)</p><p class="headingAnchor" id="H7593396"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Lymphangioleiomyomatosis (LAM) can occur sporadically (sporadic-LAM) or can complicate tuberous sclerosis complex (TSC-LAM), an inheritable disorder caused by mutations in the TSC1 or TSC2 gene. TSC-LAM is identical clinically, radiologically, and pathologically, to the sporadic variant. (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation"</a> and  <a class="medical medical_review" href="/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathogenesis</strong> – LAM occurs commonly in those with TSC. Approximately 26 to 50 percent of females and 10 to 38 percent of males with TSC develop lung cysts, but only a minority develop lung function decline. TSC-LAM typically occurs in those with TSC2 rather than TSC1 mutations. (See <a class="local">'Epidemiology'</a> above and  <a class="medical medical_review" href="/d/html/4335.html" rel="external">"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LAM is a later manifestation of TSC, typically presenting with respiratory symptoms in the third to fourth decade of life. TSC-LAM can occur in those with milder features of TSC (eg, without cognitive disability or seizures). Respiratory symptoms and signs are similar to sporadic-LAM (eg, progressive dyspnea, cough, pneumothorax, chylothorax). (See <a class="local">'Clinical manifestations'</a> above and  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On chest CT, TSC-LAM is characterized by thin-walled, multiple (≥10), diffuse, bilateral, round, well-defined cysts that vary in size and are devoid of internal structures. (See <a class="local">'Imaging characteristics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Airflow limitation and/or reduced diffusing capacity are typical, but normal pulmonary function tests (PFTs) do not preclude the diagnosis. (See <a class="local">'Pulmonary function testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whom to evaluate</strong> – For males or females with TSC and symptoms of LAM, PFTs and noncontrast chest CT should be performed  (<a class="graphic graphic_algorithm graphicRef111073" href="/d/graphic/111073.html" rel="external">algorithm 1</a>). For asymptomatic females with TSC ≥18 years of age, a screening low-dose noncontrast CT is advised. If normal, we typically repeat this screening every 5 to 10 years or when symptoms emerge. (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Screening for TSC-LAM'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Our proposed diagnostic approach is described in the algorithm  (<a class="graphic graphic_algorithm graphicRef111073" href="/d/graphic/111073.html" rel="external">algorithm 1</a>). TSC-LAM should be evaluated (and managed) in conjunction with a TSC and LAM expert.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with TSC, the identification of typical cysts consistent with LAM on high-resolution computed tomography (HRCT) chest establishes a clinical diagnosis. We also typically obtain a vascular endothelial growth factor-D (VEGF-D) level, which, if elevated (≥800 pg/mL), further supports the diagnosis. (See <a class="local">'Imaging characteristics'</a> above and <a class="local">'Vascular endothelial growth factor-D'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the HRCT chest reveals atypical cysts, a low number of cysts (&lt;10), or is suspicious for an alternate diagnosis, the approach should be individualized. Options include obtaining a VEGF-D level, lung biopsy, investigating for an alternate diagnosis, and follow-up HRCT (eg, for appearance of additional cysts). (See  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Other presentations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment of TSC-LAM and its complications is generally like that of sporadic-LAM. (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Treatment of pulmonary LAM'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with TSC-LAM with normal or mildly impaired lung function (forced expiratory volume in one second (FEV<sub>1</sub>) ≥70 percent predicted) should undergo monitoring rather than pharmacologic therapy for their pulmonary disease. (See <a class="local">'Mild lung function impairment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with moderate-to-severe progressive TSC-LAM (FEV<sub>1</sub> &lt;70 percent predicted), we recommend treatment with an mTOR inhibitor, preferably <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, rather than observation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Moderate to severe lung function impairment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with advanced lung disease refractory to mTOR inhibition, referral for lung transplantation or clinical trials is appropriate. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Treatment of pulmonary LAM'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – TSC-associated LAM is progressive but may have a more indolent course than sporadic-LAM. Patients should be monitored with pulmonary function testing and for the development of complications. (See <a class="local">'Followup and prognosis'</a> above and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other TSC-associated lung disorders</strong> – Multifocal micronodular pneumocyte hyperplasia (MMPH) may occur in up to two-thirds of patients with TSC with or without LAM; clear cell tumors of the lung have also been reported. (See <a class="local">'Other tuberous sclerosis complex-related lung disorders'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">von Ranke FM, Zanetti G, e Silva JL, et al. Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement. Lung 2015; 193:619.</a></li><li><a class="nounderline abstract_t">Henske EP, Jóźwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Primers 2016; 2:16035.</a></li><li><a class="nounderline abstract_t">Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol 2021; 123:50.</a></li><li><a class="nounderline abstract_t">Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000; 75:591.</a></li><li><a class="nounderline abstract_t">Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001; 164:661.</a></li><li><a class="nounderline abstract_t">Moss J, Avila NA, Barnes PM, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001; 164:669.</a></li><li><a class="nounderline abstract_t">Muzykewicz DA, Sharma A, Muse V, et al. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. J Med Genet 2009; 46:465.</a></li><li><a class="nounderline abstract_t">Cudzilo CJ, Szczesniak RD, Brody AS, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013; 144:578.</a></li><li><a class="nounderline abstract_t">Adriaensen ME, Schaefer-Prokop CM, Duyndam DA, et al. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol 2011; 66:625.</a></li><li><a class="nounderline abstract_t">Kristof AS, Li PZ, Major P, Landry JS. Lymphangioleiomyomatosis and Tuberous Sclerosis Complex in Quebec: Prevalence and Health-care Utilization. Chest 2015; 148:444.</a></li><li><a class="nounderline abstract_t">Ryu JH, Sykes AM, Lee AS, Burger CD. Cystic lung disease is not uncommon in men with tuberous sclerosis complex. Respir Med 2012; 106:1586.</a></li><li><a class="nounderline abstract_t">Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49:243.</a></li><li><a class="nounderline abstract_t">Tian X, Glass JE, Kwiatkowski DJ, et al. Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex. Ann Am Thorac Soc 2021; 18:815.</a></li><li><a class="nounderline abstract_t">Di Marco F, Terraneo S, Imeri G, et al. Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis. PLoS One 2016; 11:e0155331.</a></li><li><a class="nounderline abstract_t">Seibert D, Hong CH, Takeuchi F, et al. Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences. Ann Intern Med 2011; 154:806.</a></li><li><a class="nounderline abstract_t">Harris PC. The TSC2/PKD1 contiguous gene syndrome. Contrib Nephrol 1997; 122:76.</a></li><li><a class="nounderline abstract_t">Avila NA, Dwyer AJ, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology 2007; 242:277.</a></li><li><a class="nounderline abstract_t">Ryu JH, Doerr CH, Fisher SD, et al. Chylothorax in lymphangioleiomyomatosis. Chest 2003; 123:623.</a></li><li><a class="nounderline abstract_t">Tobino K, Johkoh T, Fujimoto K, et al. Computed tomographic features of lymphangioleiomyomatosis: evaluation in 138 patients. Eur J Radiol 2015; 84:534.</a></li><li><a class="nounderline abstract_t">Seaman DM, Meyer CA, Gilman MD, McCormack FX. Diffuse cystic lung disease at high-resolution CT. AJR Am J Roentgenol 2011; 196:1305.</a></li><li><a class="nounderline abstract_t">Kobashi Y, Sugiu T, Mouri K, et al. Clinicopathological analysis of multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis in Japan. Respirology 2008; 13:1076.</a></li><li><a class="nounderline abstract_t">Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173:105.</a></li><li><a class="nounderline abstract_t">Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010; 138:674.</a></li><li><a class="nounderline abstract_t">McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med 2016; 194:748.</a></li><li><a class="nounderline abstract_t">Radzikowska E, Jaguś P, Sobiecka M, et al. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis. Respir Med 2015; 109:1469.</a></li><li><a class="nounderline abstract_t">Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35:14.</a></li><li><a class="nounderline abstract_t">McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364:1595.</a></li><li><a class="nounderline abstract_t">Goldberg HJ, Harari S, Cottin V, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J 2015; 46:783.</a></li><li><a class="nounderline abstract_t">Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant 2016; 31:111.</a></li><li><a class="nounderline abstract_t">Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363:1801.</a></li><li><a class="nounderline abstract_t">Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49:255.</a></li><li><a class="nounderline abstract_t">Di Marco F, Terraneo S, Dias OM, et al. Natural history of incidental sporadic and tuberous sclerosis complex associated lymphangioleiomyomatosis. Respir Med 2020; 168:105993.</a></li><li><a class="nounderline abstract_t">Amin S, Lux A, Calder N, et al. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol 2017; 59:612.</a></li><li><a class="nounderline abstract_t">Zak S, Mokhallati N, Su W, et al. Lymphangioleiomyomatosis Mortality in Patients with Tuberous Sclerosis Complex. Ann Am Thorac Soc 2019; 16:509.</a></li><li><a class="nounderline abstract_t">Gupta N, Lee HS, Ryu JH, et al. The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge From a 15-Year Prospective Longitudinal Analysis. Chest 2019; 155:288.</a></li><li><a class="nounderline abstract_t">Muir TE, Leslie KO, Popper H, et al. Micronodular pneumocyte hyperplasia. Am J Surg Pathol 1998; 22:465.</a></li><li><a class="nounderline abstract_t">Popper HH, Juettner-Smolle FM, Pongratz MG. Micronodular hyperplasia of type II pneumocytes--a new lung lesion associated with tuberous sclerosis. Histopathology 1991; 18:347.</a></li><li><a class="nounderline abstract_t">Maruyama H, Ohbayashi C, Hino O, et al. Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2. Pathol Int 2001; 51:585.</a></li><li><a class="nounderline abstract_t">Hayashi T, Kumasaka T, Mitani K, et al. Loss of heterozygosity on tuberous sclerosis complex genes in multifocal micronodular pneumocyte hyperplasia. Mod Pathol 2010; 23:1251.</a></li><li><a class="nounderline abstract_t">Muzykewicz DA, Black ME, Muse V, et al. Multifocal micronodular pneumocyte hyperplasia: computed tomographic appearance and follow-up in tuberous sclerosis complex. J Comput Assist Tomogr 2012; 36:518.</a></li><li><a class="nounderline abstract_t">Flieder DB, Travis WD. Clear cell "sugar" tumor of the lung: association with lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia in a patient with tuberous sclerosis. Am J Surg Pathol 1997; 21:1242.</a></li></ol></div><div id="topicVersionRevision">Topic 4329 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26104489" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27226234" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34399110" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852420" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11520734" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11520735" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19419980" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539171" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lymphangioleiomyomatosis screening in women with tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21459371" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25789699" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lymphangioleiomyomatosis and Tuberous Sclerosis Complex in Quebec: Prevalence and Health-care Utilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22871462" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cystic lung disease is not uncommon in men with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24053982" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33171065" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27171001" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690595" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399043" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The TSC2/PKD1 contiguous gene syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17105849" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576391" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chylothorax in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25544557" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Computed tomographic features of lymphangioleiomyomatosis: evaluation in 138 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606293" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diffuse cystic lung disease at high-resolution CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18699800" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinicopathological analysis of multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210669" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20382711" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27628078" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26386638" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20044458" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21410393" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of sirolimus in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113676" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26156073" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21047224" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24053983" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469709" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Natural history of incidental sporadic and tuberous sclerosis complex associated lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27935023" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Causes of mortality in individuals with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571922" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lymphangioleiomyomatosis Mortality in Patients with Tuberous Sclerosis Complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29940164" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge From a 15-Year Prospective Longitudinal Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537475" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Micronodular pneumocyte hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2071093" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Micronodular hyperplasia of type II pneumocytes--a new lung lesion associated with tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11564212" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20526286" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Loss of heterozygosity on tuberous sclerosis complex genes in multifocal micronodular pneumocyte hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22992599" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Multifocal micronodular pneumocyte hyperplasia: computed tomographic appearance and follow-up in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9331299" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clear cell "sugar" tumor of the lung: association with lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia in a patient with tuberous sclerosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
